Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The major capsid protein L1 from Human papillomavirus type 18 (HPV-18) is the primary structural component of the viral outer shell, which self-assembles into pentamers to form an icosahedral capsid. This protein plays a critical role in the viral life cycle by binding to heparan sulfate proteoglycans on the host cell surface, initiating viral attachment and subsequent entry via endocytosis. HPV-18 is a high-risk oncogenic virus strongly associated with cervical, anal, vulvar, vaginal, and oropharyngeal cancers. Recombinant HPV-18 L1 proteins are expressed to form non-infectious virus-like particles (VLPs) that serve as the key antigenic component in prophylactic vaccines, such as Gardasil, Gardasil 9, and Cervarix. These vaccines stimulate the host immune system to produce neutralizing antibodies against the L1 protein, thereby preventing viral infection and reducing the incidence of HPV-associated malignancies.
Active immunization inducing neutralizing antibodies to prevent viral attachment and entry
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major capsid protein L1 (Human papillomavirus type 18) (HPV18 L1).